Article(id=1326652303110681091, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652288703246717, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2025.08.002, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1743436800000, receivedDateStr=2025-04-01, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794228157068, onlineDateStr=2026-11-09, pubDate=1754755200000, pubDateStr=2025-08-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794228157068, onlineIssueDateStr=2026-11-09, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794228157068, creator=13701087609, updateTime=1794228157068, updator=13701087609, issue=Issue{id=1326652288703246717, tenantId=1146029695717560320, journalId=1319690329412173987, year='2025', volume='46', issue='8', pageStart='737', pageEnd='868', issueExtLink='null', onlineDate='null', pubDate='1754755200000', pubDateStr='2025-08-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794228153634, creator='13701087609', updateTime=1794272975026, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1326840283779675018, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652288703246717, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1326840283783869323, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652288703246717, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=744, endPage=750, ext={EN=ArticleExt(id=1326652303303619076, articleId=1326652303110681091, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Clinical research progress of biological agents and oral small molecule drugs in pediatric dermatological related diseases, columnId=null, journalTitle=World Clinical Drug, columnName=null, runingTitle=null, highlight=null, articleAbstract=

Biological agents and oral small molecule(OSM) drugs provide a new approach for the treatment of pediatric skin diseases, such as atopic dermatitis, psoriasis, alopecia areata, and hidradenitis suppurativa. Although most biological agents and OSM drugs have only been approved for use in adult patients, with the continuous strengthening of their clinical safety evaluations and the gradual approval of their use in adolescents and children, biological agents and OSM drugs are expected to become new choices for pediatric skin disease medication in the future. This article comprehensively reviewed the biological agents and OSM drugs that have been approved by the US Food and Drug Administration in recent years or have potential for treating atopic dermatitis, psoriasis, alopecia areata, and hidradenitis suppurativa in children, in order to provide reference for the treatment of related diseases.

, authors=Qingqing XIAO1, Yan QIANG2, Shangpu GAO1, Xiaorui LI1, Sunsi WU1, Yu SONG1, *, authorsList=Qingqing XIAO, Yan QIANG, Shangpu GAO, Xiaorui LI, Sunsi WU, Yu SONG, authorCompany=null, correspAuthors=Yu SONG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1326652303630774789, articleId=1326652303110681091, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=生物制剂与口服小分子药物在儿童皮肤科相关疾病的临床研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

生物制剂及口服小分子(oral small molecule,OSM)药物为儿科皮肤病,如特应性皮炎、银屑病、斑秃以及化脓性汗腺炎等的治疗提供了全新思路。虽然大部分生物制剂及OSM药物仅获批应用于成年患者,但随着其临床安全性评估的持续强化,以及在青少年及儿童中应用的逐步获批,生物制剂及OSM药物有望成为未来儿童皮肤病用药的新选择。该文全面梳理近年来美国食品药品监督管理局批准或具备用于治疗儿童特应性皮炎、银屑病、斑秃及化脓性汗腺炎潜力的生物制剂及OSM药物,以期为相关疾病的治疗提供参考。

, authors=肖青青1, 强燕2, 高尚璞1, 李晓睿1, 吴孙思1, 宋瑜1, *, authorsList=肖青青, 强燕, 高尚璞, 李晓睿, 吴孙思, 宋瑜, authorCompany=null, correspAuthors=宋瑜, authorNote=

肖青青,主治医师,研究方向:中医药治疗皮肤疾病。

, correspAuthorsNote=
宋瑜,主任医师,研究方向:中西医结合治疗皮肤科相关疾病。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=Yzn+NMTmoH82V5R2vVsCHA==, magXml=mrYCIx7cWtj2yCrbHmVtKw==, pdfUrl=null, pdf=tKycN3YflhWZRJ2WLr5AQQ==, pdfFileSize=992835, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=hVxF0nsYCyBXzohrt41XbQ==, mapNumber=null, fund=null)}, authors=[Author(id=1326652304066982413, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652304159257103, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304066982413, language=EN, stringName=Qingqing XIAO, firstName=Qingqing, middleName=null, lastName=XIAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652304238948880, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304066982413, language=CN, stringName=肖青青, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.上海中医药大学附属龙华医院皮肤科,上海 200032, bio={"content":"

肖青青,主治医师,研究方向:中医药治疗皮肤疾病。

"}, bioImg=null, bioContent=

肖青青,主治医师,研究方向:中医药治疗皮肤疾病。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652303840489990, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, xref=1., ext=[AuthorCompanyExt(id=1326652303848878599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China), AuthorCompanyExt(id=1326652303861461512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.上海中医药大学附属龙华医院皮肤科,上海 200032)])]), Author(id=1326652304306057746, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652304389943828, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304306057746, language=EN, stringName=Yan QIANG, firstName=Yan, middleName=null, lastName=QIANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Dermatology, Skin Diseases Hospital of Tongji University, Shanghai 200443, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652304457052693, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304306057746, language=CN, stringName=强燕, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.同济大学附属上海市皮肤病医院皮肤科,上海 200443, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652303945347593, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, xref=2., ext=[AuthorCompanyExt(id=1326652303953736202, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303945347593, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Dermatology, Skin Diseases Hospital of Tongji University, Shanghai 200443, China), AuthorCompanyExt(id=1326652303962124811, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303945347593, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.同济大学附属上海市皮肤病医院皮肤科,上海 200443)])]), Author(id=1326652304532550167, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652304608047641, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304532550167, language=EN, stringName=Shangpu GAO, firstName=Shangpu, middleName=null, lastName=GAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652304670962202, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304532550167, language=CN, stringName=高尚璞, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.上海中医药大学附属龙华医院皮肤科,上海 200032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652303840489990, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, xref=1., ext=[AuthorCompanyExt(id=1326652303848878599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China), AuthorCompanyExt(id=1326652303861461512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.上海中医药大学附属龙华医院皮肤科,上海 200032)])]), Author(id=1326652304750653980, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652304809374238, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304750653980, language=EN, stringName=Xiaorui LI, firstName=Xiaorui, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652304876483103, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304750653980, language=CN, stringName=李晓睿, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.上海中医药大学附属龙华医院皮肤科,上海 200032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652303840489990, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, xref=1., ext=[AuthorCompanyExt(id=1326652303848878599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China), AuthorCompanyExt(id=1326652303861461512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.上海中医药大学附属龙华医院皮肤科,上海 200032)])]), Author(id=1326652304951980577, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652305027478051, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304951980577, language=EN, stringName=Sunsi WU, firstName=Sunsi, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652305094586916, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304951980577, language=CN, stringName=吴孙思, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.上海中医药大学附属龙华医院皮肤科,上海 200032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652303840489990, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, xref=1., ext=[AuthorCompanyExt(id=1326652303848878599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China), AuthorCompanyExt(id=1326652303861461512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.上海中医药大学附属龙华医院皮肤科,上海 200032)])]), Author(id=1326652305186861606, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652305262359080, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652305186861606, language=EN, stringName=Yu SONG, firstName=Yu, middleName=null, lastName=SONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652305325273641, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652305186861606, language=CN, stringName=宋瑜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.上海中医药大学附属龙华医院皮肤科,上海 200032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652303840489990, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, xref=1., ext=[AuthorCompanyExt(id=1326652303848878599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China), AuthorCompanyExt(id=1326652303861461512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.上海中医药大学附属龙华医院皮肤科,上海 200032)])])], keywords=[Keyword(id=1326652305430131242, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, language=EN, orderNo=1, keyword=atopic dermatitis), Keyword(id=1326652305493045803, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, language=EN, orderNo=2, keyword=psoriasis), Keyword(id=1326652305560154668, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, language=EN, orderNo=3, keyword=alopecia areata), Keyword(id=1326652305618874925, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, language=EN, orderNo=4, keyword=hidradenitis suppurativa), Keyword(id=1326652305677595182, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, language=EN, orderNo=5, keyword=biological agent), Keyword(id=1326652305732121135, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, language=EN, orderNo=6, keyword=oral small molecule drug), Keyword(id=1326652305786647088, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, language=CN, orderNo=1, keyword=特应性皮炎), Keyword(id=1326652305841173041, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, language=CN, orderNo=2, keyword=银屑病), Keyword(id=1326652305895698994, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, language=CN, orderNo=3, keyword=斑秃), Keyword(id=1326652305971196467, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, language=CN, orderNo=4, keyword=化脓性汗腺炎), Keyword(id=1326652306029916724, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, language=CN, orderNo=5, keyword=生物制剂), Keyword(id=1326652306088636981, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, language=CN, orderNo=6, keyword=小分子口服药物)], refs=[Reference(id=1326652306176717366, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=D'IPPOLITO D, PISANO M. Dupilumab(Dupixent): An interleukin-4 receptor antagonist for atopic dermatitis[J].Pharm Ther, 2018, 43(9): 532-535., articleTitle=null, refAbstract=null), Reference(id=1326652306248020535, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=SIMPSON EL, BIEBER T, GUTTMAN-YASSKY E, et al.Two phase 3 trials of dupilumab versus placebo in atopic dermatitis[J]. N Engl J, 2016, 375(24): 2335-2348., articleTitle=null, refAbstract=null), Reference(id=1326652306302546488, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Regeneron and Sanofi. A study to determine the safety and tolerability of dupilumab(REGN668/SAR231893) in patients aged≥6 to <18 years with atopic dermatitis(eczema)[EB/OL]. (2020-11-27)[2025-08-03]. https://clinicaltrials.gov/study/NCT02407756., articleTitle=null, refAbstract=null), Reference(id=1326652306357072441, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=POPOVIC B, BREED J, REES DG, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2[J]. J Mol Biol, 2017, 429(2): 208-219., articleTitle=null, refAbstract=null), Reference(id=1326652306415792698, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=SIMPSON EL, GUTTMAN-YASSKY E, EICHENFIELD LF, et al. Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition[J]. Allergy, 2023, 78(11): 2875-2891., articleTitle=null, refAbstract=null), Reference(id=1326652306495484475, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=SANTORO C. FDA Approves tralokinumab for adolescents with atopic dermatitis[EB/OL]. (2024-07-04)[2025-08-02].http://www.ajmc.com/view/fda-approves-tralokinumab-for-adolescents-with-atopic-dermatitis., articleTitle=null, refAbstract=null), Reference(id=1326652306579370556, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=PALLER AS, FLOHR C, CORK M, et al. Efficacy and safety of tralokinumabin adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial[J]. J Am Med Assoc Dermatol, 2023, 159(6): 596-605., articleTitle=null, refAbstract=null), Reference(id=1326652306654868029, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Eli Lilly and Company. Safety and efficacy of lebrikizumab(LY3650150) in combination with topical corticosteroid in moderate-to-severe atopic dermatitis[EB/OL]. (2022-05-09)[2025-08-02]. https://clinicaltrials.gov/study/NCT04250337., articleTitle=null, refAbstract=null), Reference(id=1326652306726171198, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=LI H, ZUO JP, TANG W. Phosphodiesterase-4 inhibitors forthe treatment of inflammatory diseases[J]. Front Pharmacol, 2018, 9: 1048., articleTitle=null, refAbstract=null), Reference(id=1326652306793280063, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Pfizer. Study to evaluate efficacy and safety of pf-04965842 with or without topical medications in subjects aged 12 years and older with moderate to severe atopic dermatitis(JADE EXTEND)[EB/OL]. (2024-06-11)[2025-08-02]. https://clinicaltrials.gov/study/NCT03422822., articleTitle=null, refAbstract=null), Reference(id=1326652306860388928, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=TORRELO A, REWERSKA B, GALIMBERTI M, et al.Efficacy and safety of baricitinib in combination with topicalcorticosteroids in paediatric patients with moderate-to-severeatopic dermatitis with an inadequate response to topicalcorticosteroids: Results from a phase Ⅲ, randomized,doubleblind, placebo-controlled study(BREEZE-AD PEDS)[J]. Br J Dermatol, 2023, 189(1): 23-32., articleTitle=null, refAbstract=null), Reference(id=1326652306923303489, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=GUTTMAN-YASSKY E, TEIXEIRA HD, SIMPSON EL,et al. Once-daily upadacitinib versus placebo in adolescents andadults with moderate-to-severe atopic dermatitis(Measure Up1 and Measure Up2): Results from two replicate double-blind, randomised controlled phase 3 trials[J]. Lancet, 2021,397(10290): 2151-2168., articleTitle=null, refAbstract=null), Reference(id=1326652306977829442, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=SIMPSON EL, PAPP KA, BLAUVELT A, et al. Efficacyand safety of upadacitinib in patients with moderate to severeatopic dermatitis: Analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials[J]. J Am Med Assoc Dermatol, 2022, 158(4): 404-413., articleTitle=null, refAbstract=null), Reference(id=1326652307053326915, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=REICH K, TEIXEIRA HD, DE BRUIN-WELLER M,et al. Safety and efficacy of upadacitinib in combination with topicalcorticosteroids in adolescents and adults with moderate-tosevereatopic dermatitis(AD Up): Results from a randomised double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2021, 397(10290): 2169-2181., articleTitle=null, refAbstract=null), Reference(id=1326652307112047172, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=ERIC L, SIMPSON MD, JONATHAN L, et al. A Study to evaluate the pharmacokinetics, safety and tolerability of upadacitinib in pediatric participants with severe atopic dermatitis[EB/OL]. (2024-06-17)[2025-08-03]. https://clinicaltrials.gov/study/NCT03646604., articleTitle=null, refAbstract=null), Reference(id=1326652307174961733, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=FUXENCH ZCC, LAI ZH, KUO YT, et al. Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis:results[J]. J Dermatolog Treat, 2025, 36(1): 2480744., articleTitle=null, refAbstract=null), Reference(id=1326652307237876294, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=LE AM, TORRES T. OX40-OX40L inhibition for the treatment of atopic dermatitis - Focus on rocatinlimab and amlitelimab[J]. Pharmaceutics, 2022, 14(12): 2753., articleTitle=null, refAbstract=null), Reference(id=1326652307325956679, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Amgen. A study to evaluate rocatinlimab(AMG 451)in adolescent subjects with moderate-to-severe atopic dermatitis(AD)(ROCKET-ASTRO)[EB/OL]. (2024-06-21)[2025-08-02]. https://clinicaltrials.gov/study/NCT05704738., articleTitle=null, refAbstract=null), Reference(id=1326652307401454152, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Sanofi. A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and older with moderate-to-severe atopic dermatitis(COAST 2)[EB/OL].(2024-06-21)[2025-08-02]. https://clinicaltrials.gov/study/NCT06181435., articleTitle=null, refAbstract=null), Reference(id=1326652307460174409, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Reistone Biopharma Company Limited. Evaluate efficacy and safety of oral SHR0302 in subjects aged 12 years and older with moderate to severe atopic dermatitis[EB/OL].(2023-06-01)[2025-08-02]. https://clinicaltrials.gov/study/NCT04875169., articleTitle=null, refAbstract=null), Reference(id=1326652307523088970, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=NARBUTT J, NIEDZWIEDZ M, LESIAK A, et al.Secukinumab for the treatment of psoriasis in pediatrics:patient selection and acceptability[J]. Patient Prefer Adherence, 2023, 17: 421-431., articleTitle=null, refAbstract=null), Reference(id=1326652307586003531, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=BODEMER C, KASZUBA A, KINGO K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis:52-week results from a phase 3 double-blind randomized,controlled trial[J]. J Eur Acad Dermatol Venereol, 2021,35(4): 938-947., articleTitle=null, refAbstract=null), Reference(id=1326652307648918092, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=DIOTALLEVI F, SIMONETTI O, RIZZETTO G, et al.Biological treatments for pediatric psoriasis: state of the art and future perspectives[J]. Int J Mol Sci, 2022, 23(19):121128., articleTitle=null, refAbstract=null), Reference(id=1326652307716026957, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Janssen Research & Development, LLC. A study of the safety and efficacy of ustekinumab in adolescent patients with psoriasis(CADMUS)[EB/OL]. (2015-01-29)[2025-08-02]. https://clinicaltrials.gov/study/NCT01090427., articleTitle=null, refAbstract=null), Reference(id=1326652307770552910, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Janssen Research & Development, LLC. An efficacy, safety,and pharmacokinetics study of subcutaneously administered ustekinumab in the treatment of moderate to severe chronic plaque psoriasis in pediatric participants greater than or equal to 6 to less than 12 years of age(CADMUS Jr)[EB/OL].(2021-11-01)[2025-08-02]. https://clinicaltrials.gov/study/NCT02698475., articleTitle=null, refAbstract=null), Reference(id=1326652307833467471, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=PALLER AS, SEYGER MMB, MAGARINOS GA, et al. Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial[J]. J Am Med Assoc Dermatol, 2022, 158(5): 533-541., articleTitle=null, refAbstract=null), Reference(id=1326652307896382032, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=PALLER AS, SIEGFRIED EC, LANGLEY RG, et al.Etanercept treatment for children and adolescents with plaque psoriasis[J]. N Engl J Med, 2008, 358(3): 241-251., articleTitle=null, refAbstract=null), Reference(id=1326652307955102289, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=KIVELEVITCH D, MANSOURI B, MENTER A. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis[J]. Biologics, 2014, 8: 169-182., articleTitle=null, refAbstract=null), Reference(id=1326652308013822546, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=CROWLEY EL, GOODERHAM MJ. Phosphodiesterase-4 inhibition in the management of psoriasis[J]. Pharmaceutics,2023, 16(1): 23., articleTitle=null, refAbstract=null), Reference(id=1326652308068348499, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=FIORILLO L, BECKER E, DE LUCAS R, et al. Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial[J]. J Am Acad Dermatol, 2024,90(6): 1232-1239., articleTitle=null, refAbstract=null), Reference(id=1326652308127068756, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=CAMPIONE E, LAMBIASE S, GAETA SHUMAK R, et al. A real-life study on the use of tildrakizumab in psoriatic patients[J]. Pharmaceuticals(Basel), 2023, 16(4): 526., articleTitle=null, refAbstract=null), Reference(id=1326652308194177621, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Sun Pharmaceutical Industries Limited. A study of tildrakizumab in pediatric subjects with chronic plaque psoriasis[EB/OL]. (2024-06-21)[2025-08-02]. https://clinicaltrials.gov/study/NCT03997786., articleTitle=null, refAbstract=null), Reference(id=1326652308261286486, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=GOLBARI NM, BASEHORE BM, ZITO PM.Brodalumab[EB/OL]. (2023-08-08)[2025-08-02]. https://www.ncbi.nlm.nih.gov/books/NBK470324/., articleTitle=null, refAbstract=null), Reference(id=1326652308324201047, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Kyowa Kirin. An open-label, single-dose study to evaluate safety, tolerability, and pharmacokinetics of brodalumab in pediatric subjects[EB/OL]. (2023-08-14)[2025-08-02].https://clinicaltrials.gov/study/NCT032 40809., articleTitle=null, refAbstract=null), Reference(id=1326652308408087128, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=RUSINOL L, PUIG L. Tyk2 targeting in immune-mediated inflammatory diseases[J]. Int J Mol Sci, 2023, 24(4): 3391., articleTitle=null, refAbstract=null), Reference(id=1326652308471001689, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Bristol-Myers Squibb. A study to evaluate the drug levels,efficacy and safety of deucravacitinib in pediatric participants with moderate to severe plaque psoriasis clinicaltrials[EB/OL]. (2024-07-09)[2025-08-02]. https://clinicaltrials.gov/study/NCT05478499., articleTitle=null, refAbstract=null), Reference(id=1326652308542304858, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=PRATT CH, KING LE JR, MESSENGER AG. Alopecia areata[J]. Nat Rev Dis Primers, 2017, 3: 17011., articleTitle=null, refAbstract=null), Reference(id=1326652308609413723, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG E, LEE JS, TANG M. Current treatment strategies in pediatric alopecia areata[J]. Indian J Dermatol, 2012, 57(6):459-465., articleTitle=null, refAbstract=null), Reference(id=1326652308684911196, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=CHOI JW, KIM YH, KWAK H, et al. Impact of pediatric alopecia areata on quality of life of patients and their family members: a nationwide multicenter questionnaire study[J].Ann Dermatol, 2022, 34(4): 237-244., articleTitle=null, refAbstract=null), Reference(id=1326652308760408669, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=BLAIR HA. Ritlecitinib: first approval[J]. Drugs, 2023,83(14): 1315-1321., articleTitle=null, refAbstract=null), Reference(id=1326652308827517534, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Pfizer. FDA approves Pfizer's Litfulotm(ritlecitinib) for adults and adolescents with severe alopecia areata [EB/OL].(2023-06-23)[2025-08-02]. www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and., articleTitle=null, refAbstract=null), Reference(id=1326652308886237791, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=FREITAS E, GUTTMAN-YASSKY E, TORRES T.Baricitinib for the treatment of alopecia areata[J]. Drugs,2023, 83(9): 761-770., articleTitle=null, refAbstract=null), Reference(id=1326652308944958048, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Eli Lilly and Company. A study of baricitinib(LY3009104)in children from 6 years to less than 18 years of age with alopecia areata(BRAVE-AA-PEDS)[EB/OL]. (2024-06-24)[2025-08-02]. https://clinicaltrials.gov/study/NCT05723198., articleTitle=null, refAbstract=null), Reference(id=1326652309024649825, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=AbbVie. A study to evaluate the safety and effectiveness of upadacitinib tablets in adult and adolescent participants with severe alopecia areata(Up-AA)[EB/OL]. (2024-07-04)[2025-08-02]. https://clinicaltrials.gov/study/NCT06012240., articleTitle=null, refAbstract=null), Reference(id=1326652309108535906, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=BALLARD K, SATHE NC, SHUMAN VL. Hidradenitis Suppurativa[EB/OL]. (2024-05-06)[2025-08-02]. https://www.ncbi.nlm.nih.gov/books/NBK534867., articleTitle=null, refAbstract=null), Reference(id=1326652309179839075, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=KIMBALL AB, OKUN MM, WILLIAMS DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa[J].N Engl J Med, 2016, 375(5): 422-434., articleTitle=null, refAbstract=null), Reference(id=1326652309234365028, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=BI YW, LIU J, WANG J, et al. Model-informed drug development approach supporting approval of adalimumab(HUMIRA) in adolescent patients with hidradenitis suppurativa: a regulatory perspective[J]. AAPS J, 2019, 21(5): 91., articleTitle=null, refAbstract=null), Reference(id=1326652309301473893, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=KIMBALL AB, JEMEC GBE, ALAVI A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa(SUNSHINE and SUNRISE): Week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled,double-blind phase 3 trials[J]. Lancet, 2023, 401(10378):747-761., articleTitle=null, refAbstract=null), Reference(id=1326652309364388454, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=KIMBALL AB, JEMEC GBE, SAYED CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa(BE HEARD Ⅰ and BE HEARDⅡ): Two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials[J]. Lancet, 2024,403(10443): 2504-2519., articleTitle=null, refAbstract=null), Reference(id=1326652309427303015, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=MARTORA F, SCALVENZI M, RUGGIERO A, et al.Hidradenitis suppurativa and JAK inhibitors: a review of the published literature[J]. MeMedicina(Kaunas), 2023, 59(4):801., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1326652303840489990, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, xref=1., ext=[AuthorCompanyExt(id=1326652303848878599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China), AuthorCompanyExt(id=1326652303861461512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.上海中医药大学附属龙华医院皮肤科,上海 200032)]), AuthorCompany(id=1326652303945347593, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, xref=2., ext=[AuthorCompanyExt(id=1326652303953736202, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303945347593, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Dermatology, Skin Diseases Hospital of Tongji University, Shanghai 200443, China), AuthorCompanyExt(id=1326652303962124811, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303945347593, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.同济大学附属上海市皮肤病医院皮肤科,上海 200443)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.08.002, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.08.002, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2025.08.002, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2025.08.002, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1754755200000, fullTextJson=null, articleText=null, reference=null)
收藏切换
生物制剂与口服小分子药物在儿童皮肤科相关疾病的临床研究进展
肖青青 1 , 强燕 2 , 高尚璞 1 , 李晓睿 1 , 吴孙思 1 , 宋瑜 1, *
世界临床药物 | 医药专论 2025,46(8): 744-750
收起
收藏切换
世界临床药物 |医药专论 2025 , 46 (8) : 744 -750
生物制剂与口服小分子药物在儿童皮肤科相关疾病的临床研究进展
全屏
[Author(id=1326652304066982413, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652304159257103, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304066982413, language=EN, stringName=Qingqing XIAO, firstName=Qingqing, middleName=null, lastName=XIAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652304238948880, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304066982413, language=CN, stringName=肖青青, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.上海中医药大学附属龙华医院皮肤科,上海 200032, bio={"content":"

肖青青,主治医师,研究方向:中医药治疗皮肤疾病。

"}, bioImg=null, bioContent=

肖青青,主治医师,研究方向:中医药治疗皮肤疾病。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652303840489990, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, xref=1., ext=[AuthorCompanyExt(id=1326652303848878599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China), AuthorCompanyExt(id=1326652303861461512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.上海中医药大学附属龙华医院皮肤科,上海 200032)])]), Author(id=1326652304306057746, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652304389943828, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304306057746, language=EN, stringName=Yan QIANG, firstName=Yan, middleName=null, lastName=QIANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Dermatology, Skin Diseases Hospital of Tongji University, Shanghai 200443, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652304457052693, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304306057746, language=CN, stringName=强燕, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.同济大学附属上海市皮肤病医院皮肤科,上海 200443, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652303945347593, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, xref=2., ext=[AuthorCompanyExt(id=1326652303953736202, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303945347593, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Dermatology, Skin Diseases Hospital of Tongji University, Shanghai 200443, China), AuthorCompanyExt(id=1326652303962124811, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303945347593, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.同济大学附属上海市皮肤病医院皮肤科,上海 200443)])]), Author(id=1326652304532550167, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652304608047641, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304532550167, language=EN, stringName=Shangpu GAO, firstName=Shangpu, middleName=null, lastName=GAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652304670962202, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304532550167, language=CN, stringName=高尚璞, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.上海中医药大学附属龙华医院皮肤科,上海 200032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652303840489990, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, xref=1., ext=[AuthorCompanyExt(id=1326652303848878599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China), AuthorCompanyExt(id=1326652303861461512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.上海中医药大学附属龙华医院皮肤科,上海 200032)])]), Author(id=1326652304750653980, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652304809374238, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304750653980, language=EN, stringName=Xiaorui LI, firstName=Xiaorui, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652304876483103, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304750653980, language=CN, stringName=李晓睿, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.上海中医药大学附属龙华医院皮肤科,上海 200032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652303840489990, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, xref=1., ext=[AuthorCompanyExt(id=1326652303848878599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China), AuthorCompanyExt(id=1326652303861461512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.上海中医药大学附属龙华医院皮肤科,上海 200032)])]), Author(id=1326652304951980577, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652305027478051, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304951980577, language=EN, stringName=Sunsi WU, firstName=Sunsi, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652305094586916, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652304951980577, language=CN, stringName=吴孙思, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.上海中医药大学附属龙华医院皮肤科,上海 200032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652303840489990, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, xref=1., ext=[AuthorCompanyExt(id=1326652303848878599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China), AuthorCompanyExt(id=1326652303861461512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.上海中医药大学附属龙华医院皮肤科,上海 200032)])]), Author(id=1326652305186861606, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652305262359080, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652305186861606, language=EN, stringName=Yu SONG, firstName=Yu, middleName=null, lastName=SONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652305325273641, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, authorId=1326652305186861606, language=CN, stringName=宋瑜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.上海中医药大学附属龙华医院皮肤科,上海 200032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652303840489990, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, xref=1., ext=[AuthorCompanyExt(id=1326652303848878599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China), AuthorCompanyExt(id=1326652303861461512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652303110681091, companyId=1326652303840489990, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.上海中医药大学附属龙华医院皮肤科,上海 200032)])])]
肖青青1, 强燕2, 高尚璞1, 李晓睿1, 吴孙思1, 宋瑜1, *
作者信息
  • 1.上海中医药大学附属龙华医院皮肤科,上海 200032
  • 2.同济大学附属上海市皮肤病医院皮肤科,上海 200443
通讯作者:
宋瑜,主任医师,研究方向:中西医结合治疗皮肤科相关疾病。
作者简介:

肖青青,主治医师,研究方向:中医药治疗皮肤疾病。

Clinical research progress of biological agents and oral small molecule drugs in pediatric dermatological related diseases
Qingqing XIAO1, Yan QIANG2, Shangpu GAO1, Xiaorui LI1, Sunsi WU1, Yu SONG1, *
Affiliations
  • 1.Department of Dermatology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
  • 2.Department of Dermatology, Skin Diseases Hospital of Tongji University, Shanghai 200443, China
出版时间: 2025-08-10 doi: 10.13683/j.wph.2025.08.002
文章导航
收藏切换

生物制剂及口服小分子(oral small molecule,OSM)药物为儿科皮肤病,如特应性皮炎、银屑病、斑秃以及化脓性汗腺炎等的治疗提供了全新思路。虽然大部分生物制剂及OSM药物仅获批应用于成年患者,但随着其临床安全性评估的持续强化,以及在青少年及儿童中应用的逐步获批,生物制剂及OSM药物有望成为未来儿童皮肤病用药的新选择。该文全面梳理近年来美国食品药品监督管理局批准或具备用于治疗儿童特应性皮炎、银屑病、斑秃及化脓性汗腺炎潜力的生物制剂及OSM药物,以期为相关疾病的治疗提供参考。

特应性皮炎  /  银屑病  /  斑秃  /  化脓性汗腺炎  /  生物制剂  /  小分子口服药物

Biological agents and oral small molecule(OSM) drugs provide a new approach for the treatment of pediatric skin diseases, such as atopic dermatitis, psoriasis, alopecia areata, and hidradenitis suppurativa. Although most biological agents and OSM drugs have only been approved for use in adult patients, with the continuous strengthening of their clinical safety evaluations and the gradual approval of their use in adolescents and children, biological agents and OSM drugs are expected to become new choices for pediatric skin disease medication in the future. This article comprehensively reviewed the biological agents and OSM drugs that have been approved by the US Food and Drug Administration in recent years or have potential for treating atopic dermatitis, psoriasis, alopecia areata, and hidradenitis suppurativa in children, in order to provide reference for the treatment of related diseases.

atopic dermatitis  /  psoriasis  /  alopecia areata  /  hidradenitis suppurativa  /  biological agent  /  oral small molecule drug
肖青青, 强燕, 高尚璞, 李晓睿, 吴孙思, 宋瑜. 生物制剂与口服小分子药物在儿童皮肤科相关疾病的临床研究进展. 世界临床药物, 2025 , 46 (8) : 744 -750 . DOI: 10.13683/j.wph.2025.08.002
Qingqing XIAO, Yan QIANG, Shangpu GAO, Xiaorui LI, Sunsi WU, Yu SONG. Clinical research progress of biological agents and oral small molecule drugs in pediatric dermatological related diseases[J]. World Clinical Drug, 2025 , 46 (8) : 744 -750 . DOI: 10.13683/j.wph.2025.08.002

参考文献 引证文献
排序方式:
[1]
D'IPPOLITO D, PISANO M. Dupilumab(Dupixent): An interleukin-4 receptor antagonist for atopic dermatitis[J].Pharm Ther, 2018, 43(9): 532-535.
[2]
SIMPSON EL, BIEBER T, GUTTMAN-YASSKY E, et al.Two phase 3 trials of dupilumab versus placebo in atopic dermatitis[J]. N Engl J, 2016, 375(24): 2335-2348.
[3]
Regeneron and Sanofi. A study to determine the safety and tolerability of dupilumab(REGN668/SAR231893) in patients aged≥6 to <18 years with atopic dermatitis(eczema)[EB/OL]. (2020-11-27)[2025-08-03]. https://clinicaltrials.gov/study/NCT02407756.
[4]
POPOVIC B, BREED J, REES DG, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2[J]. J Mol Biol, 2017, 429(2): 208-219.
[5]
SIMPSON EL, GUTTMAN-YASSKY E, EICHENFIELD LF, et al. Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition[J]. Allergy, 2023, 78(11): 2875-2891.
[6]
SANTORO C. FDA Approves tralokinumab for adolescents with atopic dermatitis[EB/OL]. (2024-07-04)[2025-08-02].http://www.ajmc.com/view/fda-approves-tralokinumab-for-adolescents-with-atopic-dermatitis.
[7]
PALLER AS, FLOHR C, CORK M, et al. Efficacy and safety of tralokinumabin adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial[J]. J Am Med Assoc Dermatol, 2023, 159(6): 596-605.
[8]
Eli Lilly and Company. Safety and efficacy of lebrikizumab(LY3650150) in combination with topical corticosteroid in moderate-to-severe atopic dermatitis[EB/OL]. (2022-05-09)[2025-08-02]. https://clinicaltrials.gov/study/NCT04250337.
[9]
LI H, ZUO JP, TANG W. Phosphodiesterase-4 inhibitors forthe treatment of inflammatory diseases[J]. Front Pharmacol, 2018, 9: 1048.
[10]
Pfizer. Study to evaluate efficacy and safety of pf-04965842 with or without topical medications in subjects aged 12 years and older with moderate to severe atopic dermatitis(JADE EXTEND)[EB/OL]. (2024-06-11)[2025-08-02]. https://clinicaltrials.gov/study/NCT03422822.
[11]
TORRELO A, REWERSKA B, GALIMBERTI M, et al.Efficacy and safety of baricitinib in combination with topicalcorticosteroids in paediatric patients with moderate-to-severeatopic dermatitis with an inadequate response to topicalcorticosteroids: Results from a phase Ⅲ, randomized,doubleblind, placebo-controlled study(BREEZE-AD PEDS)[J]. Br J Dermatol, 2023, 189(1): 23-32.
[12]
GUTTMAN-YASSKY E, TEIXEIRA HD, SIMPSON EL,et al. Once-daily upadacitinib versus placebo in adolescents andadults with moderate-to-severe atopic dermatitis(Measure Up1 and Measure Up2): Results from two replicate double-blind, randomised controlled phase 3 trials[J]. Lancet, 2021,397(10290): 2151-2168.
[13]
SIMPSON EL, PAPP KA, BLAUVELT A, et al. Efficacyand safety of upadacitinib in patients with moderate to severeatopic dermatitis: Analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials[J]. J Am Med Assoc Dermatol, 2022, 158(4): 404-413.
[14]
REICH K, TEIXEIRA HD, DE BRUIN-WELLER M,et al. Safety and efficacy of upadacitinib in combination with topicalcorticosteroids in adolescents and adults with moderate-tosevereatopic dermatitis(AD Up): Results from a randomised double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2021, 397(10290): 2169-2181.
[15]
ERIC L, SIMPSON MD, JONATHAN L, et al. A Study to evaluate the pharmacokinetics, safety and tolerability of upadacitinib in pediatric participants with severe atopic dermatitis[EB/OL]. (2024-06-17)[2025-08-03]. https://clinicaltrials.gov/study/NCT03646604.
[16]
FUXENCH ZCC, LAI ZH, KUO YT, et al. Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis:results[J]. J Dermatolog Treat, 2025, 36(1): 2480744.
[17]
LE AM, TORRES T. OX40-OX40L inhibition for the treatment of atopic dermatitis - Focus on rocatinlimab and amlitelimab[J]. Pharmaceutics, 2022, 14(12): 2753.
[18]
Amgen. A study to evaluate rocatinlimab(AMG 451)in adolescent subjects with moderate-to-severe atopic dermatitis(AD)(ROCKET-ASTRO)[EB/OL]. (2024-06-21)[2025-08-02]. https://clinicaltrials.gov/study/NCT05704738.
[19]
Sanofi. A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and older with moderate-to-severe atopic dermatitis(COAST 2)[EB/OL].(2024-06-21)[2025-08-02]. https://clinicaltrials.gov/study/NCT06181435.
[20]
Reistone Biopharma Company Limited. Evaluate efficacy and safety of oral SHR0302 in subjects aged 12 years and older with moderate to severe atopic dermatitis[EB/OL].(2023-06-01)[2025-08-02]. https://clinicaltrials.gov/study/NCT04875169.
[21]
NARBUTT J, NIEDZWIEDZ M, LESIAK A, et al.Secukinumab for the treatment of psoriasis in pediatrics:patient selection and acceptability[J]. Patient Prefer Adherence, 2023, 17: 421-431.
[22]
BODEMER C, KASZUBA A, KINGO K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis:52-week results from a phase 3 double-blind randomized,controlled trial[J]. J Eur Acad Dermatol Venereol, 2021,35(4): 938-947.
[23]
DIOTALLEVI F, SIMONETTI O, RIZZETTO G, et al.Biological treatments for pediatric psoriasis: state of the art and future perspectives[J]. Int J Mol Sci, 2022, 23(19):121128.
[24]
Janssen Research & Development, LLC. A study of the safety and efficacy of ustekinumab in adolescent patients with psoriasis(CADMUS)[EB/OL]. (2015-01-29)[2025-08-02]. https://clinicaltrials.gov/study/NCT01090427.
[25]
Janssen Research & Development, LLC. An efficacy, safety,and pharmacokinetics study of subcutaneously administered ustekinumab in the treatment of moderate to severe chronic plaque psoriasis in pediatric participants greater than or equal to 6 to less than 12 years of age(CADMUS Jr)[EB/OL].(2021-11-01)[2025-08-02]. https://clinicaltrials.gov/study/NCT02698475.
[26]
PALLER AS, SEYGER MMB, MAGARINOS GA, et al. Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial[J]. J Am Med Assoc Dermatol, 2022, 158(5): 533-541.
[27]
PALLER AS, SIEGFRIED EC, LANGLEY RG, et al.Etanercept treatment for children and adolescents with plaque psoriasis[J]. N Engl J Med, 2008, 358(3): 241-251.
[28]
KIVELEVITCH D, MANSOURI B, MENTER A. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis[J]. Biologics, 2014, 8: 169-182.
[29]
CROWLEY EL, GOODERHAM MJ. Phosphodiesterase-4 inhibition in the management of psoriasis[J]. Pharmaceutics,2023, 16(1): 23.
[30]
FIORILLO L, BECKER E, DE LUCAS R, et al. Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial[J]. J Am Acad Dermatol, 2024,90(6): 1232-1239.
[31]
CAMPIONE E, LAMBIASE S, GAETA SHUMAK R, et al. A real-life study on the use of tildrakizumab in psoriatic patients[J]. Pharmaceuticals(Basel), 2023, 16(4): 526.
[32]
Sun Pharmaceutical Industries Limited. A study of tildrakizumab in pediatric subjects with chronic plaque psoriasis[EB/OL]. (2024-06-21)[2025-08-02]. https://clinicaltrials.gov/study/NCT03997786.
[33]
GOLBARI NM, BASEHORE BM, ZITO PM.Brodalumab[EB/OL]. (2023-08-08)[2025-08-02]. https://www.ncbi.nlm.nih.gov/books/NBK470324/.
[34]
Kyowa Kirin. An open-label, single-dose study to evaluate safety, tolerability, and pharmacokinetics of brodalumab in pediatric subjects[EB/OL]. (2023-08-14)[2025-08-02].https://clinicaltrials.gov/study/NCT032 40809.
[35]
RUSINOL L, PUIG L. Tyk2 targeting in immune-mediated inflammatory diseases[J]. Int J Mol Sci, 2023, 24(4): 3391.
[36]
Bristol-Myers Squibb. A study to evaluate the drug levels,efficacy and safety of deucravacitinib in pediatric participants with moderate to severe plaque psoriasis clinicaltrials[EB/OL]. (2024-07-09)[2025-08-02]. https://clinicaltrials.gov/study/NCT05478499.
[37]
PRATT CH, KING LE JR, MESSENGER AG. Alopecia areata[J]. Nat Rev Dis Primers, 2017, 3: 17011.
[38]
WANG E, LEE JS, TANG M. Current treatment strategies in pediatric alopecia areata[J]. Indian J Dermatol, 2012, 57(6):459-465.
[39]
CHOI JW, KIM YH, KWAK H, et al. Impact of pediatric alopecia areata on quality of life of patients and their family members: a nationwide multicenter questionnaire study[J].Ann Dermatol, 2022, 34(4): 237-244.
[40]
BLAIR HA. Ritlecitinib: first approval[J]. Drugs, 2023,83(14): 1315-1321.
[41]
Pfizer. FDA approves Pfizer's Litfulotm(ritlecitinib) for adults and adolescents with severe alopecia areata [EB/OL].(2023-06-23)[2025-08-02]. www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and.
[42]
FREITAS E, GUTTMAN-YASSKY E, TORRES T.Baricitinib for the treatment of alopecia areata[J]. Drugs,2023, 83(9): 761-770.
[43]
Eli Lilly and Company. A study of baricitinib(LY3009104)in children from 6 years to less than 18 years of age with alopecia areata(BRAVE-AA-PEDS)[EB/OL]. (2024-06-24)[2025-08-02]. https://clinicaltrials.gov/study/NCT05723198.
[44]
AbbVie. A study to evaluate the safety and effectiveness of upadacitinib tablets in adult and adolescent participants with severe alopecia areata(Up-AA)[EB/OL]. (2024-07-04)[2025-08-02]. https://clinicaltrials.gov/study/NCT06012240.
[45]
BALLARD K, SATHE NC, SHUMAN VL. Hidradenitis Suppurativa[EB/OL]. (2024-05-06)[2025-08-02]. https://www.ncbi.nlm.nih.gov/books/NBK534867.
[46]
KIMBALL AB, OKUN MM, WILLIAMS DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa[J].N Engl J Med, 2016, 375(5): 422-434.
[47]
BI YW, LIU J, WANG J, et al. Model-informed drug development approach supporting approval of adalimumab(HUMIRA) in adolescent patients with hidradenitis suppurativa: a regulatory perspective[J]. AAPS J, 2019, 21(5): 91.
[48]
KIMBALL AB, JEMEC GBE, ALAVI A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa(SUNSHINE and SUNRISE): Week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled,double-blind phase 3 trials[J]. Lancet, 2023, 401(10378):747-761.
[49]
KIMBALL AB, JEMEC GBE, SAYED CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa(BE HEARD Ⅰ and BE HEARDⅡ): Two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials[J]. Lancet, 2024,403(10443): 2504-2519.
[50]
MARTORA F, SCALVENZI M, RUGGIERO A, et al.Hidradenitis suppurativa and JAK inhibitors: a review of the published literature[J]. MeMedicina(Kaunas), 2023, 59(4):801.
2025年第46卷第8期
55
13
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2025.08.002
  • 接收时间:2025-04-01
  • 首发时间:2026-11-09
  • 出版时间:2025-08-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2025-04-01
基金
作者信息
    1.上海中医药大学附属龙华医院皮肤科,上海 200032
    2.同济大学附属上海市皮肤病医院皮肤科,上海 200443

通讯作者:

宋瑜,主任医师,研究方向:中西医结合治疗皮肤科相关疾病。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.08.002
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏